Not buying it: Medical professionals go generic, study shows

Share this article:

Researchers at the University of Chicago Booth School of Business have news for OTC drug marketers who may feel comfortable that branded drugs are highly regarded among HCPs: Don't be.

Looking at Nielsen Homescan data that covered over 66 million shopping trips between 2004 and 2010, the researchers found that medical professionals were more likely to buy private-label headache remedies vs. branded ones than peers in non health-related fields because they know more. In addition to headache meds, researchers also looked at food and drinks and found the same thing: the more consumers know about the materials in their products, the more likely they are to use private-label versions.

In terms of headaches, researchers found that were consumers to hit the pharmacists' awareness mark—89% familiarity with the active ingredients—that branded headache medicine sales could plummet 55%, amounting to about $410 million in sales. Elevate that level of awareness to other healthcare categories like cold medications, and this comes out to an additional $340 million. Spin it further, to include food staples like sugar (food professionals are the basis of this estimate) and drinks, and the overall sales-scape would shrink by $1.1 billion.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.